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Abstract
Purpose Acute intervention with wild blueberry (WBB) has previously revealed positive cognitive and mood effects in 
typically developing children; however, it is unclear whether effects persist after daily supplementation. In addition, no data 
have been published exploring the metabolite profiles of children following berry consumption, to our knowledge. A study 
of this kind could provide insight into a mechanism of action for the cognitive and mood improvements observed previously 
in children. The aim of this pilot study was to assess cognitive performance and urinary metabolite concentrations in healthy 
7–10-year-old children across a 4 week daily WBB drink intervention.
Methods This pilot study examined the effects of daily WBB consumption for 4 weeks (766 mg total polyphenols; 253 mg 
anthocyanins; equivalent to 240 g fresh blueberries per day) on cognition and mood in 15 healthy 7–10-year-old children. 
Polyphenol metabolites were measured in 24 h urine before and after the 4 week intervention.
Results Chronic WBB-related benefits were seen on cognitively demanding trials on the modified attention network task, a 
task measuring executive functioning. Specifically, the WBB group maintained significantly higher accuracy on incongruent 
trials (96%; SE 0.03) compared with placebo participants (85%; SE 0.03; p = 0.038) after the 4 week intervention, suggesting 
WBB was of most benefit on the more difficult aspects of the task. No significant WBB-related effects were observed on the 
auditory verbal learning task or the child’s version of the positive and negative affect schedule. Urinary metabolite analyses 
indicated significant increases in different metabolites in WBB and placebo groups after 4 week consumption.
Conclusion The research demonstrates 24 h WBB bioavailability in a child cohort for the first time with increases in urinary 
hippuric acid excretion during 2 week daily WBB consumption. This study highlights the importance of conducting a larger 
study in children investigating the mechanism of action behind cognitive effects using bioavailability data.
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Introduction
Evidence highlighting the benefits of polyphenols on human 
health has been expanding across the last decade [1–5]. 
Specifically, research into polyphenol-rich blueberries has 
revealed cognitive benefits in healthy adults [6–10] and 
children [11–15]. Positive effects on mood have also been 
observed across healthy adult [16], child [17] and adoles-
cent [18] cohorts. Collectively, polyphenols have important 
implications for maintaining cognitive function and mental 
health across the lifespan.
The mechanisms of action (MOA) underlying such ben-
efits are not currently confirmed, and research has started to 
investigate biological changes that occur across the period 
that health, cognition and mood effects persist. Identifying 
specific metabolites that circulate in the body after blue-
berries have been ingested can ascertain bioavailability 
[19–21]. This is important as it may reveal the metabolites 
that are circulating at the time of observed health or cogni-
tive effects, highlighting a window, where polyphenols may 
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be distributed to areas of the body, such as the brain, help-
ing to determine a MOA. The specific mechanisms behind 
the dissemination of metabolites to these areas requires 
further exploration. At present, there is minimal literature 
on whether polyphenol metabolites are able to cross the 
blood–brain barrier (BBB) in humans, although research 
has suggested polyphenols can enter the brain endothelium 
[22] and permeate the BBB [23, 24] in animal models and 
in in-vitro models [25, 26].
Anthocyanins constitute a large proportion of the flavo-
noids found in blueberries; however, their bioavailability 
as intact compounds is known to be very low [27]. Recent 
investigations have focused on the detection, distribution and 
quantification of a wide number of anthocyanin-derived phe-
nolic metabolites coming from the degradation, chemical 
breakdown and gut microbial metabolism of anthocyanins 
in the body. These low molecular weight phenolic com-
pounds circulate at much larger concentrations than the par-
ent anthocyanins, and have been postulated to be the major 
compounds circulating in plasma up to 1 h post-berry con-
sumption [21, 27–31].
Exploration of the acute vascular benefits of blueberry 
consumption indicates that certain metabolites (particularly 
hippuric, vanillic, benzoic and ferulic acids) are present in 
urine and plasma after blueberry consumption and may 
be responsible for the acute endothelium-related vascular 
improvements observed in healthy volunteers [19, 32, 33]. It 
is unknown whether this MOA may also contribute to previ-
ously observed acute cognitive and mood effects. In Rodri-
guez-Mateos et al.’s [33] human study, metabolomic analysis 
was carried out on 63 phenolic anthocyanin derivatives in 
plasma following acute (2 h; 11 g; containing 150 mg antho-
cyanins) and chronic (28 days; 22 g/day; containing 300 mg/
day anthocyanins) WBB consumption. Measures of vascular 
endothelium function were also taken using flow-mediated 
dilation (FMD) techniques. Fourteen metabolites were sig-
nificantly associated with acute FMD improvements, 21 
metabolites with chronic improvements and 9 metabolites 
correlated with acute and chronic FMD effects. This sug-
gests that there may be some similar metabolite excretions 
following acute and chronic WBB and indicates that acute 
and chronic effects may be mediated by the same vascular 
MOA.
To date, no data have been published investigating the 
plasma or urinary metabolite profile following berry con-
sumption in children. A study of this kind could provide 
insight into a MOA for the cognitive and mood improve-
ments observed previously in 7–10 years [11–15, 17]. Better 
understanding of WBB-related changes in polyphenol excre-
tion from this experiment may inspire future trials to investi-
gate when metabolites may be in circulation and when they 
may have the potential to affect cognitive function alongside 
vascular measurement. Additionally, the longer term effects 
of blueberry polyphenols on cognition and mood in chil-
dren has not been investigated. Thus, this study is the first, 
to our knowledge, to measure cognitive performance and 
metabolite bioavailability in children following a chronic 
WBB regimen.
The aim of the current pilot study was to measure cogni-
tive performance and urinary metabolite concentrations in 
healthy 7–10-year-old children across a 4 week daily WBB 
drink intervention. It was hypothesised that executive func-
tion, memory and mood scores may improve in individuals 
assigned to the WBB treatment, based on previous research 
[11–15, 17]. It was also predicted that WBB metabolites 
may increase in a similar pattern to those identified in adults 
by Rodriguez-Mateos et al. [19, 32, 33] and Feliciano et al. 
[21]. As a pilot study, the intention was to recruit a small 
sample of participants to assess feasibility for future trials.
Methods
The research was reviewed and given a favourable ethical 
opinion for conduct by the University of Reading Research 
Ethics Committee (UREC 15/10, UREC 15/58) and was 
conducted in accordance with the Declaration of Helsinki 
and Human Tissue Act 2004.
Participants
Seventeen participants aged 7–10 years (M = 8.48, SD 0.96) 
were recruited from local primary schools in the Berkshire 
area, UK. Two participants withdrew from the study due to 
time commitment making the total recruited number 15 (8 
female). On conducting a post-hoc power analysis based on 
MANT accuracy cognitive scores, the achieved sample size 
of 15 resulted in a low power of 0.4 [F(2,26) = 3.37]. This 
should be kept in mind when interpreting results. No par-
ticipant had any food-related allergies or other health condi-
tions, e.g., diabetes, obesity, blood pressure, thyroid, kidney 
and liver diseases, or psychological diagnoses e.g., ASD, 
ADHD, which would have excluded them from the study. 
No participants were defined as having attentional deficits 
(from parent reports or CPT scores). Demographic data are 
presented in Table 1.
Design
In the current pilot study, children received a daily dose 
of either a 13.3 g WBB drink (766 mg total polyphenols; 
253 mg anthocyanins; equivalent to 240 g fresh blueber-
ries) or a placebo-matched control drink for 4 weeks using 
a between-groups, single-blind design. A single-blind design 
was utilised due to the researcher having to prepare and dis-
tribute the intervention and placebo sachets to participants. 
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The researcher only saw drinks sachets upon distribution 
after the baseline test session and after the 2 week test ses-
sion. Full blinding procedures were in place for analysis of 
the data. Measures of cognition (primary outcome) were 
recorded at baseline, 2 weeks and 4 weeks to ascertain the 
chronic effects of WBB on cognitive function and mood. 
Measures of polyphenol metabolite excretion (secondary 
outcome) were taken at baseline, 2 weeks and 4 weeks using 
24 h urinary collections collected in the 24 h period prior to 
cognitive testing (see Fig. 1). Urinary excretions covering a 
24 h period were used as they reflect the pool of circulating 
plasma metabolites in the body, from the small and large 
intestine. Using a 24 h pool of urine is more representa-
tive of chronic kinetics and better captures the half-life of 
metabolites in urine than a pool across a shorter timeframe 
[20, 34].
Testing took place after school (1530–1600), in keeping 
with previous child flavonoid research [15, 17] to minimise 
organisational demands and to maximise cognitive demand 
on participants.
Treatments
Prior to screening, participants were randomly allocated to 
receive one of two treatment drinks; a wild blueberry drink 
or a matched placebo drink.
The WBB drink contained 253 mg anthocyanins and 
was prepared by mixing 170 ml water, 13.3 g of freeze-
dried WBB and 30 ml of low-flavonoid Rocks Orange 
Squash. The placebo drink was matched to the WBB 
drink for sugars (4.79 g fructose, 4.52 g glucose), vita-
min C (45 mg), Rocks Orange Squash (30 ml) and water 
(170 ml). Drinks were presented in an opaque cup and 
Table 1  Demographic data for 
placebo and WBB participants
a Continuous Performance Task; Omissions measured as % incorrect out of 240; Commissions measured as 
% incorrect out of 30
b British Ability Scale 3; measured against norm data[39]
c Habitual fruit and vegetable intake; measured as portions per day
d Placebo n = 15; WBB n = 15; Scores from 1–10
* indicates p < 0.05; ** indicates p < 0.01
Placebo (n = 7) WBB (n = 8)
Mean SD Range Mean SD Range p values
Age (years) 8.46 0.98 7.02–9.07 8.30 0.88 7.00–9.08 0.73
CPTa
 Omissions (%) 9.88 4.34 4.58–17.08 4.64 2.87 0.42–8.33 0.02*
 Commissions (%) 65.71 20.79 40–93.33 52.92 16.76 23.33–73.33 0.21
BAS  3b 52.14 3.13 50–59 52 7.46 40–63 0.96
F & V  intakec 3.67 2.22 0.33–6 4.43 1.12 2.67–5.33 0.43
Taste  ratingsd 9.57 1.13 7–10 5.75 2.82 4–10  < 0.01**
Gender (M:F) 4:3 – – 3:5 – – –
Fig. 1  Between-groups study 
design comprising of mood, 
cognitive and urine data collec-
tion at baseline, 2 weeks and 
4 weeks
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consumed through a black straw to maintain participant 
blinding procedures. Sufficient blinding was maintained 
when drinks were made at participant homes due to the 
experiment being advertised as a ‘fruit drink study’. This 
allowed both drink conditions to remain ambiguous, even 
when both drinks were tasted at screening. As a between-
groups design was implemented, participants and their 
parents did not ever see both drinks contents.
Placebo and WBB interventions were weighed, pack-
aged and stored at – 18 °C by a researcher in the University 
of Reading kitchen, and were distributed to participants as 
2 × 14 daily sachets, alongside a 500 ml bottle of Rock’s 
Orange Squash, a 30 ml measurer, an opaque flask, straws 
and preparation instructions. Chronic procedures were in 
compliance with storage recommendations; all parents/
guardians confirmed that the treatment sachets were retained 
in a freezer throughout the intervention period. All chronic 
interventions were prepared daily at the participants’ own 
homes by their parent(s)/guardian(s), and were consumed 
within 20 min of preparation. This was confirmed by drinks 
logs which stipulated the time the drinks were prepared and 
whether they were completely or partially consumed. In 
addition, there was no evidence that compliance was dif-
ferent between the groups. The time of daily consumption 
over the supplementation period was not stipulated for ease, 




All tasks used in the current study have been previously 
validated in our laboratory and have shown to be sensitive 
to nutritional interventions. Reys Auditory Verbal Learning 
Task (AVLT) assesses short-term verbal memory through 
word list learning, and requires participants to recall lists of 
15 nouns after being presented audibly. Outcome measures 
for the AVLT include various sub-measures of verbal mem-
ory and interference, and were calculated according to Lezak 
[35]. In addition, implemented in the current study was a 
type of visual flanker task: the modified attention network 
task (MANT). The MANT measures executive function, 
attention and inhibition and produces outcome measures of 
accuracy (proportion of correct hits, 0–1) and reaction time 
(RT) for correct targets (RTs < 200 ms removed). Full details 
of both the AVLT and MANT can be seen in Barfoot et al. 
[15]. The Positive and Negative Affect Schedule for Children 
(PANAS-C) [36] was used as a measure of mood in the cur-
rent study. This questionnaire asks participants to rate, on a 
scale of 1 (not at all) to 5 (very much), how much they feel 
each item (e.g., happy, miserable) in the current moment and 
is deemed suitable for children in the 7–10 age range. Higher 
scores indicated higher levels of positive or negative affect 
(for full details see [17]).
Procedure
Children were individually tested in a quiet cubicle space in 
the Nutrition and Cognition lab in the University of Reading 
Psychology Department on four separate visits—screening, 
baseline, 2 week and 4 week sessions.
Screening
All children took part in a screening session 1 week before 
the baseline test session. At screening, participants com-
pleted a computerised Continuous Performance Task (CPT) 
that was used to assess, but not diagnose, possible attentional 
deficits which may lead to exclusion from the study. Three 
sub-tests of The British Ability Scale 3 (BAS 3; matrices, 
pattern construction and verbal similarities) [37–39] were 
also administered to measure general cognitive ability. Sev-
enteen participants were initially screened. Randomisation 
of intervention group membership was conducted using a 
random number generator prior to the screening session. 
Participant dropout occurred following screening (n = 1) 
and following baseline (n = 1); therefore, 15 participants 
completed the full study and had data sets analysed. All par-
ticipants were of typical general cognitive ability for their 
age (Table 1). Participants did significantly differ between 
treatment groups on the CPT omissions subscale in that pla-
cebo participants made more errors of omission than WBB 
participants (Table 1); however, upon further exploration 
this did not appear to affect MANT or AVLT performance 
between groups at baseline.
A practice of the PANAS-C and cognitive task battery 
occurred at screening to ensure understanding of the tasks 
and to reduce practice effects [40]. A taste rating scale 
(10-point Likert scale ranging from ‘1—It was horrible’ 
to’10—I loved it’) was distributed to participants at the end 
of screening to assess their liking of the treatment drinks. 
Here, children were required to taste both treatment drinks 
in a randomised order. An exclusion criterion was applied, 
wherein any child who reported a rating of less than 4 for 
their assigned drink was excluded from the study. Four out 
of ten was chosen as a clear distinction between the children 
being indifferent to the drink (which a score of 5 out of 10 
would represent) and actively disliking the drink. However, 
no child rated their drink less than 4 and so no child was 
excluded on this basis. Children were told that they would 
be randomly allocated to receive one of the two fruit drinks 
for the duration of the 4 week intervention. Urine collec-
tion and treatment procedures were explained to parents and 
children at screening.
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Participants were required to follow a low-flavonoid diet 
for 48 h before each future test session. This consisted of 
participants avoiding high flavonoid foods, such as berry 
fruits, fruit juices, tea, coffee and cocoa. Low flavonoid sug-
gestions were provided, such as potatoes, carrots, bananas 
and yoghurt. This 48 h period included the 24 h urine col-
lections. Time of urinations and food consumption during 
24 h urine collections were recorded by parents to check 
schedule adherence. Three day food diaries were used to 
record participants’ typical food consumption between base-
line, 2 week and 4 week sessions (excluding low-flavonoid 
diet days). Food diaries were consistently completed on two 
weekdays and one weekend day, and these were used to 
assess habitual fruit and vegetable consumption (Table 1).
Urine collection procedure
Three urine containers (1 × 100 ml, 2 × 2L) were distrib-
uted to parents to collect their child’s fasted 0 h, 0–12 h and 
12–24 h urine, 1 day prior to 0, 2 and 4 week test visits. Each 
2L urine container contained 375 mg of L-ascorbic acid to 
preserve the urine across the collection period.
Due to the level of continuous monitoring and support 
required of parents, urine collection days were encouraged to 
take place on a Sunday when both the child and parent were 
at home and ended Monday morning prior to school. Urine 
collection procedures across Sunday and Monday collection 
days can be seen in Fig. 2. The first urination of the day was 
excluded from urine collections due to the accumulation of 
compounds from the previous night. After the first urina-
tion of the day, participants were asked to use the fasted 0 h 
container to collect urine before consuming food. After this 
urination, participants were then permitted to start eating 
their (non-standardised) low-flavonoid diet for the day, and 
were instructed to use the 0–12 h container to collect each 
subsequent urination. The first urination in the 0–12 h con-
tainer was permitted to be no later than 9am. Twelve hours 
after the initial 0–12 h urination, participants were asked to 
use the 12–24 h container to collect subsequent urinations. 
Parents completed the urine collection log detailing the time 
of the child’s first urination in each pot, and food consumed 
throughout the day, to ensure compliance to time and dietary 
requirements.
Participants were asked to store the urine containers in a 
cool bag with ice blocks (both provided) throughout the 24 h 
collection, and parents were encouraged to replenish with a 
new ice block every 3–4 h (excluding overnight). Follow-
ing all collections, parents dropped their child’s samples at 
the University of Reading Psychology Department at 9am 
the following day, where they were processed and stored 
at –80◦C in the Food and Nutritional Sciences department.
During the second and third urine collections, partici-
pants consumed their assigned treatment drink immediately 
prior to commencement of the 0–12 h collection (no later 
than 9am). This was so comparisons could be made between 
the metabolites excreted across 0–24 h at 0 weeks (no treat-
ment) and those excreted following WBB or placebo con-
sumption at 2 and 4 weeks.
Urine processing procedure
Total volumes of baseline, 0–12 h and 12–24 h collection 
samples were recorded, and 100 ml of each respective con-
tainer was retained for further processing after mixing. Sam-
ples were centrifuged and measured into 2 × 14 ml falcon 
tubes, where 1 × 14 ml falcon tube contained approximately 
100ul formic acid (FA) to reach a pH of 2.4. One ml of 
urine from each falcon tube was then aliquoted into labelled 
Eppendorf tubes and stored at − 80 °C for future analysis.
Test day procedure
Baseline (week 0), 2 week and 4 week test sessions were 
conducted after school hours on a Monday, following urine 
collections on the Sunday. At the baseline session the 
completed 3 day food diary and urine collection log were 
retrieved from parents. Participants completed the PANAS-
C and cognitive task battery before consuming either the 
placebo or WBB treatment drink. At the end of the baseline 
test session, the drinks-making procedure was explained 
to parents and children, and the necessary equipment was 
Fig. 2  Urine collection day procedure for 0, 2 and 4 weeks into the 
intervention
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distributed. Neither parents nor children knew which treat-
ment they were receiving. Parents continued supplementing 
their children at home with the same treatment that their 
child had received at the baseline test session over the next 
2 weeks.
At the 2 week session, completed food diaries and urine 
collection logs were retrieved from parents. Children com-
pleted the PANAS-C and a different matched version of 
the cognitive task battery. Participants had not received a 
treatment drink on this day to avoid testing acute effects. 
Participants consumed their treatment drink at home after 
their test session and continued their treatment schedule for 
a further 2 weeks.
The same procedure ensued at the 4 week visit. At the 
end of this visit both the participant and their parent(s) were 
debriefed on the aims of the study and were reimbursed with 
£40 cash, a t-shirt and a cap for taking part.
Urinary analysis procedure
Urinary samples were analysed according to a validated 
method as described in Feliciano et al. [41]. The detection of 
urine polyphenol metabolites was performed on an Agilent 
6550 iFunnel Accurate-Mass Quadrupole Time-of-Flight 
Mass Spectrometer (Q-TOF MS) through an electro-spray 
interface with Jet Stream technology after separation on a 
1290 Infinity UHPLC system (Agilent, Waldbronn, Ger-
many). Polyphenol concentrations were calculated using 
authentic standard curves. These curves were quantified 
within the Agilent software by calculating the mass of a 
metabolite compound and the time taken to elute within 
the gas chamber to produce a urinary concentration value. 
Recoveries were calculated by normalising urinary concen-
trations in terms of volume excreted during each collection 
timepoint. Twenty seven metabolites were quantified based 
on previous findings [20, 21].
Statistical analysis
All data were analysed using SPSS (Version 22.0).
Fifteen participants (7 placebo, 8 WBB) were included in 
the analyses of demographic and mood variables. Baseline 
differences in age, attention (CPT; omissions, commissions), 
general ability (BAS 3) and taste (1–10) were examined 
using independent t tests with Drink (placebo and WBB) 
as the IV.
Mood (PANAS-C), cognitive (AVLT, MANT) and 
metabolite data were analysed by linear mixed models 
(LMMs) using an unstructured covariance matrix to model 
repeat measures. Separate Linear Mixed Models (LMMs) 
were performed for each dependent variable (DV) in the 
PANAS-C (PA, NA) and MANT (accuracy, reaction time). 
Separate LMMs were performed for each outcome measure 
of the AVLT, for each metabolite compound and for total 
polyphenols (sum of all compounds at each respective time-
point). Baseline performance was included in all LMMs as a 
fixed factor. For urinary metabolite analyses, within-group 
post-hoc comparisons were performed, following previously 
published methods [20, 21].
Drink (placebo, WBB), Time (2 weeks, 4 weeks) and 
Drink × Time were included as Fixed Factors in LMMs 
to compare the effects of treatment across the intervention 
period. For the MANT, Congruency (congruent, incon-
gruent), Load (high load, medium load) and Target Time 
(120 ms, 500 ms) were also included as Fixed Factors in 
the model to detect changes in relation to cognitive load as 
in Whyte et al. [12, 13] and Barfoot et al. [15]. These vari-
ables were also contained within interactions with Drink and 
Time to assess cognitive load differences between treatment 
groups across the intervention. Participant was included as 
a random factor to accommodate the dependency of indi-
vidual data. Fourteen participants (7 placebo, 7 WBB) 
were included in the analyses of MANT variables. This was 
due to corruption of a single participant’s MANT data file 
at the 2 week timepoint, rendering raw data void for this 
participant.
All post-hoc pairwise comparisons were corrected for 





Demographic data are presented in Table 1. There were no 
significant differences at baseline between treatment groups 
for age, inhibition (CPT commissions), general ability (BAS 
3) or habitual fruit and vegetable consumption. There were 
significant differences at baseline between groups for sus-
tained attention (CPT omissions), where placebo partici-
pants had a higher rate of failing to respond to non-target 
stimuli than WBB participants. There were also significant 
differences between groups for taste ratings, where drink 
‘liking’ ratings were higher for placebo compared to WBB.
Raw data for cognitive and mood variables are presented 
in Table 2.
MANT
Correlational analyses revealed that there was no trade-off 
between accuracy and reaction time (RT) scores at baseline 
(r = 0.26, p = 0.35).
European Journal of Nutrition 
1 3
Table 2  Mean (SD) data for Placebo and WBB participants’ performance for mood and cognitive outcome variables at baseline, 2 weeks and 
4 weeks
Outcome variables Baseline 2 weeks 4 weeks
Placebo (n = 7) WBB (n = 8) p Placebo (n = 7) WBB (n = 8) p Placebo (n = 7) WBB (n = 8) p
Mood
 PA 51.86 (19.91) 54.63 (17.30) 0.78 49.29 (19.42) 52.63 (17.56) 0.73 46.57 (19.58) 49.38 (20.35) 0.79
 NA 20 (12.83) 15.75 (0.89) 0.37 18.29 (6.21) 15.50 (0.53) 0.23 17.86 (7.56) 16.63 (3.29) 0.68
MANT accuracy 
(0–1):
(n = 7) (n = 7) (n = 7) (n = 7) (n = 7) (n = 7)
 Overall 0.81 (0.11) 0.92 (0.04) 0.02 0.85 (0.17) 0.97 (0.02) 0.10 0.89 (0.12) 0.97 (0.01) 0.1
 Congruent trials 0.85 (0.08) 0.96 (0.03)  < 0.01 0.89 (0.14) 0.98 (0.02) 0.13 0.91 (0.12) 0.98 (0.02) 0.19
 Incongruent 
trials
0.77 (0.16) 0.88 (0.06) 0.1 0.82 (0.20) 0.96 (0.02) 0.08 0.86 (0.13) 0.96 (0.02) 0.06
 High load trials 0.82 (0.12) 0.92 (0.05) 0.06 0.86 (0.15) 0.96 (0.03) 0.12 0.90 (0.10) 0.96 (0.02) 0.12
 Medium load 
trials
0.80 (0.11) 0.93 (0.03) 0.01 0.85 (0.18) 0.98 (0.02) 0.09 0.87 (0.15) 0.98 (0.01) 0.09
 Fast (120 ms) 
trials
0.79 (0.12) 0.90 (0.07) 0.07 0.83 (0.18) 0.96 (0.03) 0.09 0.86 (0.14) 0.97 (0.02) 0.06
 Slow (500 ms) 
trials
0.82 (0.11) 0.95 (0.02) 0.01 0.87 (0.16) 0.97 (0.01) 0.12 0.91 (0.10) 0.97 (0.01) 0.18
 RT (ms): overall 632.30 (104.28) 644.77 (93.81) 0.82 614.32 (95.05) 621.59 (80.53) 0.88 612.30 (83.86) 609.19 (66.09) 0.94
 Congruent trials 612.64 (108.83) 596.45 (94.02) 0.77 598.17 (98.53) 603.92 (85.93) 0.91 600.57 (83.50) 589.15 (67.12) 0.78
 Incongruent 
trials
651.95 (101.79) 693.09 (100.01) 0.46 630.46 (92.17) 639.25 (79.22) 0.85 624.02 (86.24) 629.22 (67.02) 0.9
 High load trials 637.12 (106.45) 656.71 (92.14) 0.72 616.21 (97.28) 620.65 (79.08) 0.93 616.44 (91.83) 621.00 (68.37) 0.92
 Medium load 
trials
627.48 (102.78) 632.84 (97.47) 0.92 612.43 (93.27) 622.53 (83.42) 0.83 608.16 (77.72) 597.38 (65.20) 0.78
 Fast (120 ms) 
trials
601.88 (112.65) 647.93 (90.28) 0.42 617.59 (113.43) 623.69 (78.52) 0.91 597.39 (83.22) 598.59 (64.91) 0.98
 Slow (500 ms) 
trials
662.71 (105.10) 641.62 (105.45) 0.71 611.04 (79.49) 619.49 (84.34) 0.85 627.21 (86.39) 619.79 (69.01) 0.86
AVLT (n = 6) (n = 8) (n = 7) (n = 8) (n = 7) (n = 8)
 Word span (A1) 3.50 (0.84) 3.63 (1.51) 0.86 4.14 (1.07) 4.00 (0.76) 0.77 4.00 (1.15) 4.13 (1.13) 0.84
(n = 6) (n = 8) (n = 6) (n = 8)
 Words learnt 
(A5–A1)
3.50 (1.87) 5.75 (3.24) 0.16 4.00 (1.67) 5.50 (2.33) 0.21 3.17 (3.66) 3.50 (2.20) 0.84
(n = 7) (n = 8) (n = 7) (n = 8)
 Final acquisition 
(A5)
7.00 (2.45) 9.38 (2.50) 0.1 7.57 (2.82) 9.50 (2.51) 0.18 6.71 (3.50) 7.63 (2.07) 0.54
 Total acquisition 
(sum of list A: 
1–5)
30.83 (9.85) 34.88 (6.56) 0.37 32.00 (9.00) 34.25 (7.96) 0.62 30.00 (9.88) 31.50 (6.65) 0.73
(n = 7) (n = 8)
 PI (A1–B1) − 0.71 (1.25) − 0.88 (2.17) 0.87 0.29 (1.38) − 0.50 (1.20) 0.26 0.71 (0.76) 1.25 (2.12) 0.54
 RI (A5–A6) 1.14 (1.95) 1.88 (2.47) 0.54 2.43 (3.26) 1.50 (1.20) 0.47 2.14 (2.61) 1.88 (2.53) 0.84
 Total list A recall 
(sum list A: 
1–7)
36.14 (18.89) 48.63 (8.53) 0.12 42.29 (12.84) 47.88 (11.73) 0.39 39.29 (14.28) 41.75 (9.79) 0.7
 Total list recall 
(sum list A: 
1–7 + B1)
39.86 (21.21) 53.13 (9.49) 0.13 46.14 (13.50) 52.38 (11.90) 0.36 42.57 (14.86) 44.63 (9.36) 0.75
 Recognition 10.29 (2.36) 11.13 (1.89) 0.46 9.71 (2.50) 10.50 (2.07) 0.52 8.86 (2.79) 10.38 (1.69) 0.22
Long delay recall 
(A7)
4.86 (2.61) 6.25 (2.71) 0.33 5.14 (2.61) 5.63 (2.33) 0.71 4.71 (1.89) 4.50 (2.27) 0.85
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Accuracy (proportion correct 0–1)
Analyses of MANT accuracy scores showed three sig-
nificant (p < 0.05) Drink interactions: (Drink × Con-
gruency [F(1,104.15) = 10.74, p < 0.01], Drink × Load 
[F(1,104.38) = 4.84, p = 0.03], Drink × Target time 
[F(1,105.82) = 9.39, p < 0.01] as seen in Fig. 3.
Placebo participants performed at 91% accuracy on 
congruent trials which significantly fell to 85% on incon-
gruent trials (p < 0.01). No such difference in performance 
was observed between congruent and incongruent trials 
for WBB participants, with participants performing at 
96% accuracy on both incongruent and congruent trials. 
Indeed, WBB participants were found to be significantly 
more accurate on incongruent trials than placebo partici-
pants by 11% (p = 0.038; Fig. 3a.)
WBB-treated participants were also significantly more 
accurate than placebo on medium load trials (p = 0.05; 
Fig. 3b). A similar pattern was evident for high load tri-
als, though this effect did not reach significance (p = 0.18).
As shown in Fig. 3c, significantly increased accuracy 
was also observed on 500 ms trials compared to 120 ms 
trials for placebo participants only (p < 0.01). The absence 
of between-trial differences in WBB participants (p = 0.87) 
suggests a maintenance of performance across different 
speeds of stimulus presentation within this group. WBB-
treated participants showed 96% accuracy compared to 
86% accuracy in placebo-treated participants on 120 ms 
trials (p = 0.04), highlighting the benefit of WBB on trials 
of faster presentation.
Regardless of treatment, accuracy was found to signifi-
cantly increase at 4 weeks (M = 0.92, SE 0.02) compared to 
2 weeks [M = 0.91, SE 0.02; F(1,119.71) = 5.34, p = 0.02], 
participants performed significantly more accurately on 
congruent trials (M = 0.93, SE 0.02) than incongruent trials 
[M = 0.91, SE 0.02; F(1,106.44) = 13.39, p < 0.01], and on 
500 ms trials (M = 0.93, SE 0.02) compared to 120 ms tri-
als [M = 0.91, SE 0.02; F(1, 106.77) = 7.49, p < 0.01]. Load 
was not found to predict performance across the intervention 
period [F(1,104.14) = 0.32, p = 0.58].
Reaction time (RT; ms)
Significantly slower performance was observed on high 
load incongruent trials (M = 638.29, SE 26.64) compared 
to medium load incongruent trials [M = 614.52, SE 26.63; 
(F(2,104.30) = 4.50, p = 0.01] for placebo participants only 
(p = 0.01). This suggests that placebo participants performed 
worse on conditions of high demand. However, no such load 
differences were evident for WBB participants (high load 
incongruent M = 641.94, SE 25.27; medium load incongru-
ent M = 641.27, SE 25.10), suggesting that this group’s RTs 
were unaffected, and potentially protected, from the manipu-
lation of increased cognitive load.
Table 2  (continued)
Outcome variables Baseline 2 weeks 4 weeks
Placebo (n = 7) WBB (n = 8) p Placebo (n = 7) WBB (n = 8) p Placebo (n = 7) WBB (n = 8) p
 Short delay 
recall (A6)
(n = 5) (n = 8) (n = 6) (n = 8) (n = 6) (n = 8)
6.80 (2.17) 7.50 (1.31) 0.48 6.00 (1.26) 8.00 (2.73) 0.12 5.33 (2.73) 5.75 (2.76) 0.78
Fig. 3  Mean (± SEM) MANT accuracy (0–1, proportion correct) for WBB and placebo participants on a congruency, b load and c target time 
variables; *Significance p < 0.05; # denotes a trend 0.05 > p < 0.1
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As expected, from performance in previous cognitive 
studies [11–13], significantly quicker reaction times were 
evident for congruent trials (M = 607.50, SE 18.05) when 
compared to incongruent trials [M = 634.01, SE 18.06; 
F(1,112) = 19.88, p < 0.001]. There were no other significant 
predictors of MANT RT performance.
AVLT
No treatment-related effects were observed on AVLT out-
come measures.
Mood
Positive (PA) and Negative (NA) Affect
Regardless of Drink, PA was lower at 4 weeks (M = 48.06, 
SE 1.94) compared to 2  weeks (M = 51.04, SE 1.94), 
an effect that narrowly missed achieving significance 
[F(1,15) = 4.27, p = 0.057]. No other significant results were 
observed for PA or NA measures.
Urinary polyphenol metabolites
Significant hippuric acid increases were observed after 
2 week daily WBB supplementation. Changes in excretion 
also occurred for placebo participants, where concentra-
tions of benzoic acid, 3-(4-hydroxyphenyl) propionic acid, 
syringic acid and isoferulic acid 3-O-β-d-glucuronide were 
significantly higher after 4 week daily placebo consumption.
A total of 27 phenolic metabolites were quantified in 
urine at weeks 0, 2 and 4 including pyrogallol, phenylacetic, 
valerolactone, benzoic acid, propionic acid, catechol, cin-
namic acid and hippuric acid derivatives. Raw data for indi-
vidual metabolite concentrations across weeks 0, 2 and 4 
can be seen in Table 3.
There were no significant differences at baseline between 
treatment groups for total polyphenols excreted [t(11) = 1.39, 
p = 0.19]. Baseline variability appeared to be higher in the 
placebo group (SD 48,632) compared to the WBB group 
(SD 17,757); however, data were considered to be homog-
enous in a Levene’s test for equality of variances (F = 3.21, 
p = 0.1).
As shown in Fig. 4a, analysis revealed no significant 
changes in excretion of polyphenols over the 4  weeks 
for either WBB [F(2,7.57) = 3.11, p = 0.10 or placebo 
F(2,7.23) = 1.64, p = 0.26], although there is a notable trend 
for an increase in polyphenol excretion following WBB 
treatment and a decrease in polyphenol excretion for those 
consuming the placebo treatment (Fig. 4b).
Significantly higher concentrations of hippuric acid was 
observed at 2 weeks compared to 4 weeks in participants 
under a chronic WBB regimen [F(1,11.45) = 7.99, p = 0.016; 
Fig. 5].
Some metabolites showed a trend for an increase in the 
WBB group; higher concentrations of dihydro caffeic acid 
3-O-sulfate were observed at 4 weeks compared to partici-
pants in the placebo group. Although a Drink × Time inter-
action was near-significant [F(1,11.79) = 4.45, p = 0.057], no 
further significant or trending post-hoc results were observed 
(Online Resource 1). Higher concentrations of benzoic acid 
[F(1,12.81) = 10.89, p < 0.01; Fig. 6a], 3-(4-hydroxyphenyl) 
propionic acid [F(1,11.69) = 43.78, p < 0.01; Fig. 6b], syrin-
gic acid [F(1,11.42) = 6.85, p = 0.02; Fig. 6c] and isoferu-
lic acid 3-O-β-d-glucuronide [F(1,24) = 3.63, p = 0.069; 
Fig. 6d] were observed in placebo participants at week 4 
compared to week 2.
Discussion
The current pilot study administered a daily dose of flavo-
noid-rich wild blueberry to typically developing 7–10-year-
old children for 4 weeks following a randomised, placebo-
controlled, between-groups design, to investigate the effects 
of chronic consumption on mood, cognition and urinary 
metabolites.
Improvements in accuracy were observed on the MANT 
following WBB intervention, specifically on incongruent, 
fast and medium load trials. This suggests WBB was of most 
benefit to children under conditions of increased cognitive 
demand and on trials requiring higher speed of processing 
and alertness, as also observed on the MANT by Whyte 
et al. [13] and Barfoot et al. [15], respectively, in children 
aged 7–10. The current results do not match with Whyte 
et al.’s [14] recent findings in children in this age range, 
which revealed that WBB participants performed faster than 
placebo participants on congruent trials of an Attention Net-
work Task (ANT) but not on incongruent trials. A reason 
this might be is that the ANT may not have been cognitively 
demanding enough to detect incongruent WBB effects in 
Whyte et al.’s [14] study. As the authors note, the ANT did 
not include the additional load and noise variables that are 
present in the MANT, potentially reducing the complexity 
of the task and sensitivity to blueberry effects.
Interestingly, when directly comparing congruent and 
incongruent MANT trials, performance was consistent 
for WBB, whereas performance significantly dropped off 
on incongruent trials following placebo. This suggests the 
WBB group did not succumb to manipulation of cognitive 
load. Children were able to maintain performance across 
easy and difficult trial types, which provides further support 
that WBB was of benefit to children under conditions of 
increased cognitive demand.
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Such effects were also evident through manipulation of 
congruency and visual load. Placebo performed significantly 
slower on high load incongruent trials when compared to 
medium load incongruent trials. This was an expected 
effect of the task due to the increased cognitive resource 
required for high load trials. However, no such difference 
was observed for WBB, again suggesting maintenance of 
performance on the most cognitively demanding conditions 
Table 3  Mean (± SD) urinary polyphenol concentrations at week 0, week 2 and week 4 for placebo and WBB participants
*Significance at the p < 0.05 level for Time × Drink interactions. Details of within and between group significance is provided in Figs. 5, 6a–d 
and in Online Resource 1
a Metabolites that had higher concentrations after repeated WBB consumption
b Metabolites that had higher concentrations after repeated placebo consumption
Urinary concentration (μg/24 h)
Placebo (n = 7) WBB (n = 8)
Week 0 (n = 6) Week 2 (n = 7) Week 4 (n = 7) Week 0 (n = 7) Week 2 (n = 8) Week 4 (n = 6)
Pyrogallol derivatives
 Pyrogallol-O-2-sulfate 3172 ± 1949 3043 ± 1745 2126 ± 964 5750 ± 6337 2807 ± 3595 3660 ± 4490
 1-Methylpyrogallol-O-sulfate 941 ± 581 902 ± 452 673 ± 428 2424 ± 2457 1055 ± 1102 1599 ± 1635
Phenylacetic acid derivatives
 Homovanillic acid 522 ± 291 1406 ± 1660 626 ± 405 462 ± 310 624 ± 348 431 ± 224
 3-hydroxyphenylacetic acid 57 ± 36 107 ± 50 126 ± 21 92 ± 68 139 ± 143 161 ± 102




17 ± 38 67 ± 60 7 ± 6 3 ± 5 20 ± 23 25 ± 41
Benzoic acid derivatives
 Benzoic  acida,b,* 53 ± 14 52 ± 9 64 ± 13 48 ± 30 59 ± 18 52 ± 19
Protocatechuic  acidb 616 ± 208 828 ± 284 662 ± 258 903 ± 592 577 ± 513 799 ± 790
 2-hydroxybenzoic acid 0.02 ± 0.02 0.03 ± 0.04 0.03 ± 0.05 0.35 ± 0.40 0.23 ± 0.26 0.27 ± 0.31
 4-hydroxybenzoic acid 7 ± 10 18 ± 32 13 ± 16 10 ± 12 12 ± 16 22 ± 26
 Vanillic acid 646 ± 312 1152 ± 1420 846 ± 360 413 ± 227 393 ± 285 482 ± 282
 4-METHYLGALLIC-3-O-sulfate 670 ± 356 778 ± 705 359 ± 225 994 ± 637 859 ± 1001 1813 ± 2746
 2,4-dihydroxybenzoic acid 9 ± 7 8 ± 8 8 ± 5 8 ± 9 8 ± 4 7 ± 4
 Syringic  acidb,* 265 ± 284 393 ± 377 406 ± 237 87 ± 47 301 ± 270 220 ± 249
Propionic acid derivatives
 3-(4-hydroxyphenyl) propionic  acidb 310 ± 133 340 ± 146 435 ± 83 235 ± 265 285 ± 205 175 ± 134
Catechol derivatives
 4-methylcatechol-O-sulfate 265 ± 156 346 ± 172 203 ± 44 164 ± 73 222 ± 84 171 ± 86
Cinnamic acid derivatives
 t-ferulic acid 51 ± 22 38 ± 18 44 ± 15 24 ± 13 28 ± 14 37 ± 23
 Ferulic acid 4-O-sulfate 100 ± 150 439 ± 751 324 ± 544 28 ± 33 83 ± 115 71 ± 62
 Ferulic acid 4-O-β-d-glucuronide 2114 ± 1671 2155 ± 962 3123 ± 2358 713 ± 691 600 ± 382 513 ± 349
 Dihydro ferulic acid 4-O-β-d-
glucuronide
7194 ± 7401 6879 ± 6718 4095 ± 2589 1214 ± 1001 1911 ± 1122 1310 ± 721
 Isoferulic acid 134 ± 118 130 ± 95 168 ± 78 52 ± 49 49 ± 81 29 ± 22
 Isoferulic acid 3-O-β-d-glucuronideb 673 ± 800 459 ± 284 689 ± 546 130 ± 161 126 ± 96 68 ± 59
 Dihydro isoferulic acid 3-O-sulfate 2445 ± 2407 2281 ± 1462 2925 ± 2305 414 ± 338 513 ± 372 349 ± 411
 Dihydro isoferulic acid 3-O-β-d-
glucuronide
3692 ± 4801 7797 ± 4515 6578 ± 4864 917 ± 285 3176 ± 3079 2175 ± 1612
 Dihydro caffeic acid 3-O-sulfate 13,987 ± 11,617 18,134 ± 12,800 10,451 ± 5701 6525 ± 7049 13,265 ± 13,497 19,219 ± 25,072
 Chlorogenic acid 10,685 ± 23,737 214 ± 368 217 ± 300 1 ± 1 31 ± 45 58 ± 114
Hippuric acid derivatives
 Hippuric  acida,* 1226 ± 340 1171 ± 443 1158 ± 389 987 ± 394 1347 ± 262 1171 ± 262
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of the task. These findings support Whyte et al.’s [13] and 
Barfoot et al.’s [15] research in children, which suggest 
supplementation with WBB can overcome the increased 
demand participants experience in conditions of high cog-
nitive load, and specifically highlights the potential for WBB 
benefits across conditions of increasing complexity on the 
MANT, such as high load and incongruence. Furthermore, 
it is encouraging that similar WBB benefits have emerged 
in a smaller sample size than prior research at a lower power 
of 0.4 [F(2,26) = 3.37]. In addition, reassuring is that typical 
performance patterns on the MANT, regardless of treatment, 
were evident. Performance was significantly more accurate 
and faster on congruent trials compared to incongruent tri-
als suggesting high internal validity for the task, irrespec-
tive of the small sample size. These observations indicate 
that the MANT may be sensitive at detecting WBB-related 
change on trials of higher difficulty using a lower number 
of participants than previously predicted. It is interesting, 
however, that typical load effects (worse performance on 
high load trials) did not occur regardless of drink. This ques-
tions whether the disparity between congruent and incongru-
ent trials is larger than that between load trials and whether 
incongruent trials are more difficult than trials of high, 
medium and low load. This may be why load effects did not 
persist in this small sample. WBB participants performance 
was maintained on the more difficult high load, incongruent 
trials suggesting that in combination, the required complex-
ity to detect a WBB effect was potentially achieved. Future 
studies might like to assess the difficulty of MANT trial type 
combinations to see if WBB is of most benefit on the most 
complex trials.
Accuracy was revealed to be significantly higher in the 
WBB group compared to the placebo group on 120 ms trials. 
In addition, accuracy did not differ between fast (120 ms) 
and slow (500 ms) trials of the MANT for WBB partici-
pants, as opposed to placebo participants whose accuracy 
significantly dropped on fast trials. These findings indicate 
WBB participants were able to perform more accurately on 
faster paced trials across a 4 week WBB supplementation. 
Interestingly, a significant Drink × Target Time interaction 
also occurred in children in Barfoot et al. [15], where signifi-
cantly quicker RT occurred on the faster 120 ms trials after 
acute (2 h) WBB supplementation, at no cost to accuracy. 
This indicated improved speed of processing and mental 
alertness on faster trials under an acute design. It is interest-
ing that WBB RT benefits occurred after a one-off dose, 
whereas WBB accuracy was higher under a 4 week regimen, 
suggesting different facets of executive function (including 
time to process, ability to integrate information to make a 
correct response and mental alertness) may respond differ-
ently to acute and chronic WBB interventions.
Overall, a lack of treatment-related findings were 
observed for mood and memory outcomes (PANAS-C and 
AVLT, respectively). Previous effects observed on these 
measures in children, using parallel group designs were in 
Fig. 4  a Mean (± SEM) raw 
total polyphenol excretion at 
baseline, 2 weeks and 4 weeks 
for placebo and WBB par-
ticipants, b mean (± SEM) total 
polyphenol change from base-
line at 2 weeks and 4 weeks for 
placebo and WBB participants
Fig. 5  Significantly more hippuric acid was observed in WBB par-
ticipants’ 24  h urinary excretion compared at 2  weeks compared to 
4  weeks (p < 0.01) and compared to placebo participants (p = 0.04); 
*denotes significance at p < 0.05
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larger samples (AVLT, n = 54 [15]; PA, n = 54 [17]); there-
fore, the small sample size could explain absence of treat-
ment effects here for these tasks. In addition, the WBB ben-
efits observed in the aforementioned research occurred in 
acute trials, and futher work is needed to explore memory 
and mood in children following chronic WBB supplementa-
tion. In the present study, positive affect was found to signifi-
cantly decline at 4 weeks compared to 2 weeks, regardless of 
treatment. This could be explained by increased feelings of 
tedium and repetitiveness as the novelty of the experiment 
diminished over time. It is important to note that if this was 
the case, these feelings did not influence negative affect as 
these scores did not change over the intervention period.
Increased excretion of total polyphenols was observed 
for WBB participants over the course of the intervention, 
but this did not reach statistical significance, whilst placebo 
participants showed a non-significant decline. This implies 
that repeated daily consumption of a WBB drink across 
4 weeks may increase the total concentration of polyphe-
nolic metabolites excreted in 7–10-year-old children, but a 
larger sample is required to confirm the subtle indications 
from this pilot. Specifically, the degree to which changes 
in total metabolites are driven by individual metabolites in 
children following WBB requires further investigation, as 
the present study provided limiting findings regarding this 
from 27 compounds.
Here, higher concentrations of hippuric acid were 
observed at 2 weeks following WBB relative to 4 weeks. 
As per a-priori statistical methods, comparisons were not 
made directly with baseline, rather baseline was included 
in the model as a covariate (LMM fixed factor). Previous 
research has shown changes in hippuric acid following WBB 
Fig. 6  a Higher benzoic acid was seen for WBB participants at 
2  weeks compared to placebo participants (p = 0.066). However, 
at 4  weeks, significantly higher excretion was observed in placebo 
participants in comparison to WBB participants (p = 0.038), and 
when compared to 2  week excretion levels (p < 0.01); b excretion 
of 3-(4-hydroxyphenyl) propionic acid was significantly higher at 
4 weeks for placebo participants compared to 2 week excretion lev-
els (< 0.01) and to WBB (p < 0.01). Excretion of this compound was 
found to significantly reduce from 2 to 4 weeks in participants under 
a chronic WBB regimen (p = 0.01); c higher excretion of syringic 
acid was observed at 4 weeks compared to 2 weeks for placebo par-
ticipants (p = 0.06); d participants under placebo treatment excreted 
a significantly higher concentration of isoferulic acid 3-O-β-d-
glucuronide at 4  weeks compared to 2  weeks (p = 0.018) and com-
pared to WBB (p = 0.017)
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interventions. Rodriguez-Mateos et al. [33] observed a rise 
in plasma hippuric acids across 4 weeks of freeze-dried 
WBB intervention in healthy adults (22 g/day; containing 
300 mg/day anthocyanins). Interestingly, vascular improve-
ments (FMD) occurred after 1 week of daily supplementa-
tion, rising further after 2 weeks, but plateauing between 2 
and 4 weeks and it was postulated that 2 weeks may be an 
optimal timeframe to sustain beneficial endothelial change. 
High concentrations of hippuric acid following 2 weeks of 
daily WBB in the current study partly supports this theory. 
It would be of interest to explore whether metabolites may 
mediate vascular and cognitive changes specifically at the 
2 week timepoint in children. Similarly, Feliciano et al. [21] 
reported that hippuric acid was found to be the largest con-
tributor (~ 86%) to the pool of circulating metabolites in 
plasma following 30 day WBB supplementation in adults. 
Such increases in hippuric acid may be due to interactions 
between blueberry conjugates and gut microbiota. Indeed, 
hippuric acid is a metabolite that is derived from gut micro-
bial metabolism. The efficiency of the gut to metabolise 
polyphenols may have, therefore, been positively affected 
and this warrants further exploration. Interestingly in Feli-
ciano et al.’s [21] study, adult concentrations of hippuric 
acid were much higher at day 0 (M = 55,827 ± SEM = 7000) 
and day 30 (M = 62,840 ± SEM = 8552) following the 
WBB regimen compared to child concentrations in the 
current study (day 0, M = 987 ± SEM = 394; day 30, 
M = 1171 ± SEM = 262). Concentrations were similarly 
low in children following the placebo regimen in the cur-
rent study (day 0, M = 1226 ± 340; day 30, M = 1158 ± 389). 
This suggests that children may have lower absorption rates 
than adults and requires further investigation. It is important 
to acknowledge that the current study and Feliciano et al.’s 
study did not employ the same methodology, so compari-
sons between participant concentrations across studies must 
be interpreted with caution. Similar increases in hippuric 
acid in adult cohorts have been observed in plasma follow-
ing a 12 week daily bilberry intervention [42], and in urine 
after an 8 week high-polyphenol diet intervention [43]. This 
highlights hippuric acid as a potential metabolite of interest 
when considering the chronic improvements that have been 
observed in health [44] and cognitive domains [6–10].
At present, a best practice for converging metabolite and 
cognitive data is yet to be established. It is vital that nutri-
tional interventions investigating physiological or cognitive 
measures include a placebo control; however, the method by 
which treatment and placebo data are analysed currently dif-
fers. Metabolomic comparisons are often made within-par-
ticipants, identifying compounds that have changed across 
time for individuals in each treatment group. As metabolite 
variability is high across individuals and dependent upon 
many variables (e.g., diet, genetics), between-group com-
parisons would not account for such variability and would 
provide an unreliable estimate of treatment effect. On the 
other hand, cognitive comparisons need to occur within and 
between treatment groups to examine changes across time 
and in comparison to a similarly performing control group. 
It is well known that large inter-individual variation exists 
between individuals across investigations into polyphenol 
metabolism (for review see [45]). Genetic variability in the 
expression of metabolic enzymes and transporters is thought 
to play a part in post-absorptive metabolism, and these meta-
bolic functions are likely to work differently depending on 
the individual, food source and dose [46]. High inter-indi-
vidual variability is, therefore, expected in investigations of 
this kind, highlighting the importance of within-participant 
comparisons. Such individual variation may account for the 
lack of significant increases in some metabolites observed 
between 2 and 4 weeks. Future research should consider 
employing a chronic, within-groups, crossover design (with 
an appropriate washout period) so that cognitive and metab-
olite data can be assessed in the same participant sample 
using placebo and WBB arms.
It is feasible that flavonoids derived from other dietary 
sources in the 48 h prior to the 4 week urine collection, may 
have converged with the flavonoids present in WBB, pro-
ducing increased excretion of metabolite compounds. From 
3 day food diary data, participants can be said to have aver-
age fruit and vegetable consumption when compared to the 
latest Health Survey for England [47] which shows children 
aged 5–15 consume ~ 3.1 portions of fruit and vegetables a 
day. It could, therefore, be possible that children consumed 
an average amount of fruits and vegetables in the days prior 
to urine collections, leading to interactions between blue-
berry and other flavonoids.
Similarly, other dietary constituents may have interfered 
with metabolite excretion in the placebo group, where ben-
zoic acid, 3-(4-hydroxyphenyl) propionic acid, syringic acid 
and isoferulic acid 3-O-β-D-glucuronide excretion increased 
at 4 weeks. Indeed, isoferulic acid is found in many low 
flavonoid dietary sources, such as peanuts, wheat [48] and 
pineapples [49], and benzoic acid is often used as a preserva-
tive in cordial squash. Although participants were asked to 
follow a low flavonoid diet for 48 h prior to urine collections, 
they were still permitted to consume foods deemed ‘low fla-
vonoid’ that may have produced high levels of polyphenolic 
metabolite compounds. It may, therefore, be of use in the 
future to derive a standardised low polyphenol diet based 
on high polyphenolic compound levels rather than high fla-
vonoid food status alone. It is also important to consider 
the necessity of adding squash to both WBB and placebo 
treatment drinks. Rock’s squash contains small amounts of 
organic acids [50] which may interfere with metabolite 
levels directly or interact with other dietary constituents 
to produce confounded levels. In the current and previ-
ous studies, Rock’s squash has been used for palatability 
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purposes. Exploration of other low polyphenol additions to 
increase palatability of placebo and WBB drinks is, there-
fore, warranted.
Interestingly, placebo participants failed to respond to 
non-target stimuli at a significantly higher rate than WBB 
participants on the demographic measure of sustained atten-
tion. This suggests that those assigned to the placebo group 
were, by chance, of a lower attentional ability. This was 
supported by significantly lower accuracy on the MANT 
for this group at baseline, a task requiring attention. How-
ever, MANT accuracy was consistently high in both placebo 
(range = 80.75–88.52%) and WBB (range = 92.38–96.82%) 
groups across the course of the intervention, suggesting this 
characteristic may not have been a detriment to placebo par-
ticipants beyond baseline. Indeed, no significant differences 
were observed between treatment groups at the 2 or 4 week 
timepoint when including baseline as a fixed factor in the 
LMM.
An additional limitation is that the placebo drink was 
rated as significantly more likeable compared to the WBB 
drink. This could be due to the texture of the WBB drink, 
which had a somewhat grainier consistency. Future studies 
should consider including other palatability measures, such 
as texture and smell to determine aspects of the drinks that 
participants do not like, to further inform adequate placebo-
control matching. The important aspect of the current study 
is that no participant rated their assigned treatment drink 
below a 4 (out of 10), indicating their treatment was drink-
able. Importantly, this finding suggests that WBB-related 
improvements are not due to high drink likeability.
Future research should build on these initial findings by 
converging cognitive effects with metabolite excretion and a 
measure of cerebral blood flow (CBF), such as arterial spin 
labelling (ASL), regional functional magnetic resonance 
imaging (fMRI), or magnetoencephalography (MEG), to 
better inform the field of a chronic mechanism of action 
(MOA). Investigation into how polyphenolic metabolites 
enter the BBB and impact the brain is still in its’ infancy; 
however, a promising review by Carregosa et al. [51] has 
identified mechanisms by which low-molecular weight poly-
phenol metabolites, such as hippuric acid, may attenuate 
neuroinflammation via action within the central nervous 
system’s microglia cells. These immune cells are responsi-
ble for the surveillance and action on neurotoxic and neu-
roprotective processes, rendering them key to brain repair, 
renewal and disease progression. Investigation of the afore-
mentioned neuropsychological and molecular techniques 
alongside measures of cognitive performance would permit 
measurement of the specific flavonoid metabolites that are 
circulating in the body when cognitive effects are observed, 
and would elucidate whether regional CBF effects are also 
present across the same time frame. This would allow 
researchers to postulate the specific flavonoid metabolites 
that may be able to cross the BBB and exert vasodilatory 
effects on the brain in the presence or absence of cognitive 
improvements.
The current pilot study aimed to measure the cognitive 
ability and urinary metabolite concentrations of healthy 
7–10 years following a 4 week daily WBB regimen. It 
was predicted that cognition may improve following WBB 
supplementation. Significant improvements in cognition 
were observed in children consuming WBB, specifically 
on trials requiring high cognitive demand, as has been 
seen in previous child acute WBB research [13]. WBB-
related memory or mood effects were not evident, despite 
the previous benefits that transpired in acute child trials 
[15, 17]. The study also aimed to explore urinary excre-
tion levels in a child cohort under a chronic WBB design 
for the first time. Hippuric acid levels were found to be 
significantly higher at 2 weeks, aligning with previous 
chronic adult berry [21, 42] and polyphenol-rich diet [43] 
research. Children may excrete polyphenol derivatives 
in a similar pattern to adults and hippuric acid may be a 
potential metabolite of interest when considering health 
and cognitive benefits across adult and child populations. 
However, further work is required to elucidate the specific 
metabolomic processes occurring in a child population 
across chronic timeframes under WBB and placebo inter-
ventions. Specifically, research should aim to investigate 
metabolite levels, cognitive performance and endothe-
lium-related change in conjunction to try and elucidate 
the MOA behind WBB benefits.
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